Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Three US Fingolimod Approvals Raise Legal Stakes

Approvals for Biocon, HEC and Sun Pharma

Executive Summary

The first three FDA approvals for generic fingolimod generics come amid ongoing legal uncertainty over Novartis’ Gilenya blockbuster multiple sclerosis treatment.

You may also be interested in...



Novartis Q4 Preview: Launches Likely To Deliver

Having had a very fruitful year in terms of regulatory approvals, the Swiss major will reveal how successful its new products have been commercially. Of particular interest will be the performance of eye drug Beovu as it takes on Bayer's rival Eylea.

Duo Fight For Fingolimod Share In Canada

Teva and Pharmascience are going head-to-head in a battle to capture the market for generic Gilenya fingolimod capsules in Canada.

Sandoz Sets Generics Focus As US Sale Awaits

New Sandoz chief Richard Saynor says the division is undergoing a transformation towards building a generics-focused business. Meanwhile, the company is still waiting to close the sale of its US oral-dose and dermatology operations to Aurobindo. 

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB149428

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel